Role of urinary podocalyxin in early diagnosis of diabetic nephropathy

Hydroxytyrosol's Protective Effect Through Podocalyxin and Pentraxin-3 in Kidney Damage Resulting From Corn Syrup Administration

INTRODUCTION

In this study, we aimed to investigate whether hydroxytyrosol (HT) has a protective effect on corn syrup-induced kidney damage in rats and the role of podocalyxin (PCX) and pentraxin-3 (PTX3) in this possible effect.

METHODS

Rats were divided into four groups with six rats in each group: 1) control, 2) HT, 3) corn syrup, and 4) corn syrup + HT. Rats were given 30% corn syrup added to their drinking water for six weeks. HT was given orally at 4 ml/kg/day, alone and together with corn syrup. PCX and PTX3 in the renal tissue were assessed through histopathological examination. Biochemical parameters were also examined in the sera with the ELISA method.

RESULTS

In this study, it was observed that PCX and PTX3 levels, which increased as a result of corn syrup administration, decreased after HT treatment (p < 0.001). The increase in amylase, lipase, and insulin levels because of corn syrup consumption decreased with HT consumption (p = 0.001, p < 0.001, p = 0.003, respectively). It was determined that the increase in erythrocyte extravasation, exudate accumulation, and fibrosis observed in the kidney tissue with corn syrup application decreased as a result of HT application (p < 0.001).

CONCLUSION

It is thought that HT has a protective effect against kidney damage caused by corn syrup and that PCX and PTX3 may play a role in this effect.

A pilot study of changes in urinary podocalyxin levels during normal pregnancy and labor

Introduction: Increased urinary podocalyxin, a surrogate marker of podocyte detachment, has been shown in preeclampsia and eclampsia, but there is a paucity of data of the effect of normal pregnancy on its urinary excretion. We aimed to describe these changes in this pilot study.

Methods: Urine podocalyxin levels were measured in 115 pregnant women. Of these, 12 women were in the second trimester of gestation, 57 in the third trimester and 46 women were in labor.

Results: The median [IQR] urinary podocalyxin levels were 0.81 [0.27, 3.68], 0.92 [0.44, 5.49] and 64.7 [30.5, 106.3] ng/mg creatinine in the second trimester, third trimester, and during labor, respectively (p<0.0001). Patients with hematuria during labor had higher levels of urinary podocalyxin (128.6 [79.8, 169.6] ng/mg creatinine. There was a moderate correlation between gestational age and urinary podocalyxin levels (r=0.63, p<0.0001).

Conclusion: Urinary podocalyxin levels were low in normal pregnancies and increased significantly during labor and with hematuria.

Emerging Biomarkers for Early Detection of Chronic Kidney Disease

Chronic kidney disease (CKD) is a major and serious global health problem that leads to kidney damage as well as multiple systemic diseases. Early diagnosis and treatment are two major measures to prevent further deterioration of kidney function and to delay adverse outcomes. However, the paucity of early, predictive and noninvasive biomarkers has undermined our ability to promptly detect and treat this common clinical condition which affects more than 10% of the population worldwide. Despite all limitations, kidney function is still measured by serum creatinine, cystatin C, and albuminuria, as well as estimating glomerular filtration rate using different equations. This review aims to provide comprehensive insight into diagnostic methods available for early detection of CKD. In the review, we discuss the following topics: (i) markers of glomerular injury; (ii) markers of tubulointerstitial injury; (iii) the role of omics; (iv) the role of microbiota; (v) and finally, the role of microRNA in the early detection of CKD. Despite all novel findings, none of these biomarkers have met the criteria of an ideal early marker. Since the central role in CKD progression is the proximal tubule (PT), most data from the literature have analyzed biomarkers of PT injury, such as KIM-1 (kidney injury molecule-1), NGAL (neutrophil gelatinase-associated lipocalin), and L-FABP (liver fatty acid-binding protein).